鲁索替尼乳膏Opzelura在美国获批治疗轻中度特应性皮炎

Ruxolitinib Cream Opzelura is a cream formulation of a JAK1/JAK2 inhibitor. On September 21, 2021, Incyte announced that the U.S. FDA has approved ruxolitinib Cream Opzelura for the short-term and discontinuous chronic treatment of mild to moderate atopic dermatitis. Specifically, it is suitable for non-immunocompromised patients 12 years of age and older whose condition cannot be adequately controlled by topical prescription drugs or after progression on previous therapy. It is the first and currently only JAK inhibitor external preparation approved by the US FDA.

The recommended usage and dosage of Ruxolitinib Cream Opzelura is: apply a thin layer of Ruxolitinib Cream to the affected area no more than 20% of the body surface area twice a day, and the weekly dosage does not exceed 60g. Patients should note: Ruxolitinib cream Opzelura cannot be used in ophthalmology, oral cavity, nor vaginal use. This drug can only be used topically. Ruxolitinib cream should be discontinued when signs and symptoms of atopic dermatitis subside. If patients receive this drug treatment and there is no improvement in their symptoms within 8 weeks, they should go to the hospital for a detailed examination and the doctor will diagnose whether it is necessary to change the drug treatment.

As with most drugs, there are some side effects that may occur with Opzelura, including: sore or swollen throat, diarrhea, bronchitis, ear infections, increased eosinophil count, hives, folliculitis, tonsillitis, runny nose, etc. Due to individual differences, each patient will experience different side effects, more or less side effects, and severity of side effects after receiving ruxolitinib cream Opzelura treatment. This is mainly determined by the patient's own situation. If patients experience serious adverse reactions during treatment with ruxolitinib cream Opzelura, they should go to the hospital immediately for formal treatment.

The above is an introduction to Ruxolitinib Cream Opzelura. If patients want to know more drug information about Ruxolitinib Cream Opzelura (such as precautions, drug prices, purchase channels, etc.), they can consult the Medical Companion Travel Service.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: